Results for Chemicals & Small Molecules ( 91165 )
- From: DKK2,708.00
CG001 is a small molecule inhibitor that targets Wnt/β-catenin pathway. It inhibits TCF/β-catenin mediated transcription by competing with β-catenin for CBP (CREB binding protein) but not p300 binding with an IC50 of 3 µM. It can be used to specifically evaluate the role of CBP/beta-catenin association on WNT signaling and cell physiology.
- From: DKK10,388.00
CG001 is a small molecule inhibitor that targets Wnt/β-catenin pathway. It inhibits TCF/β-catenin mediated transcription by competing with β-catenin for CBP (CREB binding protein) but not p300 binding with an IC50 of 3 µM. It can be used to specifically evaluate the role of CBP/beta-catenin association on WNT signaling and cell physiology.
- From: DKK5,048.00
CG001 is a small molecule inhibitor that targets Wnt/β-catenin pathway. It inhibits TCF/β-catenin mediated transcription by competing with β-catenin for CBP (CREB binding protein) but not p300 binding with an IC50 of 3 µM. It can be used to specifically evaluate the role of CBP/beta-catenin association on WNT signaling and cell physiology.
- From: DKK6,218.00
Retaspimycin hydrochloride (also known as IPI-504), a hydroquinone hydrochloride salt derivative of 17-AAG, is a novel, potent and selective inhibitor of Hsp90 that binds at the N-terminal ATP/ADP-binding site of Hsp90. Once in the systemic circulation, IPI-504 is deprotonated and converted into the free base IPI-504 which is subsequently oxidized to 17-AAG.
- From: DKK3,803.00
Retaspimycin hydrochloride (also known as IPI-504), a hydroquinone hydrochloride salt derivative of 17-AAG, is a novel, potent and selective inhibitor of Hsp90 that binds at the N-terminal ATP/ADP-binding site of Hsp90. Once in the systemic circulation, IPI-504 is deprotonated and converted into the free base IPI-504 which is subsequently oxidized to 17-AAG.